Inside Precision Medicine — a specialist publication covering the full spectrum of precision medicine and advanced therapeutics — included Ali Pashazadeh, CEO of Treehill Partners, in its feature examining the state of the gene therapy sector entering 2026. The article surveys the year of retraction and recovery in gene therapy and asks what the sector needs to do differently going forward.
Ali characterised 2025 as a year of retraction for gene therapy — one in which a significant concentration of capital, management attention, and strategic focus had been deployed across the sector, and where that period had, to a large extent, come to an end. While acknowledging the positive signals emerging in the second half of 2025 — including Eli Lilly’s acquisitions of gene therapy assets in ophthalmology and rare disease — his view reflects the rigorous commercial accountability Treehill applies to assessing whether sector enthusiasm translates into sustainable investment frameworks.
The article notes that cautious optimism is returning as pharma licensing activity increases, and as the sector matures beyond first-generation programmes into more differentiated modalities including prime editing, in vivo CRISPR, and next-generation AAV vectors. For Treehill, the message is consistent: the science is advancing, but the path to patient access and commercial viability requires the same discipline it demands in any other therapeutic area.
Read the full article on: https://www.insideprecisionmedicine.com/topics/translational-research/riding-the-gene-therapy-rollercoaster-into-2026/
📌 Treehill Partners – helping biopharma companies optimize development strategies for both regulatory approval and commercial success, unlocking transaction optionality with strategic and financial players.